Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin in Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
NCT05284552Phase 2Recruiting
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tinzaparin in epithelial ovarian cancer (EOC) (2 arms). Primary endpoint: Cancer Antigen 125 at 14 weeks. Started Jul 2022; status: recruiting.
02
Drugs
tinzaparin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT05284552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284552.